Overview of Diabetes and Diabetic Care

Resource	Address
Abdul-Ghani M, DeFronzo RA. Is it time to change the type 2 diabetes treatment paradigm? Yes! GLP-1 RAs should replace metformin in the type 2 diabetes algorithm. *Diabetes Care.* 2017;40:1121-1127.	https://care.diabetesjournals.org/content/40/8/1121.long
Afkarian M, et al. Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014. *JAMA*. 2016;316:602-610.	https://jamanetwork.com/journals/jama/fullarticle/2542635
American Diabetes Association (ADA). 10. Cardiovascular disease and risk management: standards of medical care in diabetes-2020. *Diabetes Care.* 2020;43(suppl 1):S111-S134.	https://care.diabetesjournals.org/content/43/Supplement_1/S111
American Diabetes Association (ADA). 11. Microvascular complications and foot care: Standards of medical care in diabetes-2019. *Diabetes Care.* 2019;42(suppl 1):S124-S138.	https://care.diabetesjournals.org/content/42/Supplement_1/S124
American Diabetes Association (ADA). 12. Older adults: Standards of medical care in diabetes-2019. *Diabetes Care.* 2019;42(suppl 1):S139-S147.	https://care.diabetesjournals.org/content/42/Supplement_1/S139
Arauz-Pacheco C, et al. Treatment of hypertension in adults with diabetes. *Diabetes Care.* 2003;26(suppl 1):S80-S82.	https://care.diabetesjournals.org/content/26/suppl_1/s80
Boudi FB, Ahsan CH. Risk factors for coronary artery disease. Medscape eMedicine, 2019.	https://emedicine.medscape.com/article/164163-overview
Burke KR, et al. SGLT2 inhibitors: A systematic review of diabetic ketoacidosis and related risk factors in the primary literature. *Pharmacotherapy.* 2017;37:187-194.	https://accpjournals.onlinelibrary.wiley.com/doi/abs/10.1002/phar.1881
Centers for Disease Control and Prevention (CDC). Diabetes State Burden Toolkit: Health Burden.	https://nccd.cdc.gov/Toolkit/DiabetesBurden/Home/Health

Centers for Disease Control and Prevention (CDC). National Diabetes Statistics Report—2020.	https://www.cdc.gov/diabetes/data/statistics/statistics-report.html
Centers for Disease Control and Prevention (CDC). National Diabetes Statistics Report—2017.	https://dev.diabetes.org/sites/default/files/2019-06/cdc-statistics-report-2017.pdf
Creutzfeldt W. The incretin concept today. *Diabetologia*. 1979;16:75-85.	https://link.springer.com/article/10.1007%2FBF01225454
Davies MJ, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care.* 2018;41:2669-2701.	https://care.diabetesjournals.org/content/41/12/2669
Defronzo RA. From the triumvirate to the ominous octet: A new paradigm for the treatment of type 2 diabetes mellitus. *Diabetes*. 2009;58:773-795.	https://diabetes.diabetesjournals.org/content/58/4/773
Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. *Diabetes Care*. 2003;26:2929-2940.	https://care.diabetesjournals.org/content/26/10/2929
Fehse F, et al. Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. *J Clin Endocrinol Metab.* 2005;90:5991-5997.	https://academic.oup.com/jcem/article/90/11/5991/2838406
Fong DS, et al. Diabetic retinopathy. *Diabetes Care.* 2003;26(suppl 1):S99-S102.	https://care.diabetesjournals.org/content/26/suppl_1/s99
Han S, et al. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. *Diabetes.* 2008;57:1723-1729.	https://diabetes.diabetesjournals.org/content/57/6/1723
Inzucchi SE, et al. Management of hyperglycemia in type 2 diabetes, 2015: A patient-centered approach: Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetes Care.* 2015;38:140-149.	https://care.diabetesjournals.org/content/38/1/140

Kendall DM, et al. Clinical application of incretin-based therapy: Therapeutic potential, patient selection and clinical use. *Am J Med.* 2009;122(6 suppl):S37-S50.	https://www.amjmed.com/article/S0002-9343(09)00279-4/fulltext
Kieffer TJ, Habener JF. The glucagon-like peptides. *Endocr Rev*. 1999;20:876-913.	https://academic.oup.com/edrv/article/20/6/876/2530991
Kim Y, Babu AR. Clinical potential of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetes. *Diabetes Metab Syndr Obes.* 2012;5:313-327.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3437808/
Lee YS, Jun HS. Anti-Inflammatory effects of GLP-1-based therapies beyond glucose control. *Mediators Inflamm.* 2016. Article ID 3094642.	https://www.hindawi.com/journals/mi/2016/3094642/
Lee YJ, et al. Regulatory mechanisms of Na^+/glucose cotransporters in renal proximal tubule cells. *Kidney Int Suppl.* 2007;106:S27-S35.	https://www.kidney-international.org/article/S0085-2538(15)52548-9/fulltext
Mayfield JA, et al. Preventive foot care in people with diabetes. *Diabetes Care.* 2003;26(suppl 1):S78-S79.	https://care.diabetesjournals.org/content/26/suppl_1/s78
Moghissi E. Management of type 2 diabetes mellitus in older patients: current and emerging treatment options. *Diabetes Ther*. 2013;4:239-256.	https://link.springer.com/article/10.1007%2Fs13300-013-0039-6
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Diabetes in America, 3rd edition. 2018.	https://www.niddk.nih.gov/about-niddk/strategic-plans-reports/diabetes-in-america-3rd-edition
Wright EM. Renal Na^+-glucose cotransporters. *Am J Physiol Renal Physiol.* 2001;280:F10-F18.	https://journals.physiology.org/doi/full/10.1152/ajprenal.2001.280.1.F10

Diabetes and Cardiovascular Disease/Risk

Resource	Address
Arnett DK, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *J Am Coll Cardiol.* 2019;74:e177-e232.	https://www.ahajournals.org/doi/10.1161/CIR.0000000000000677
Buse JB, et al. 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care.* 2020;43:487-493.	https://care.diabetesjournals.org/content/43/2/487
DCCT Group. Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality. *JAMA* 2015;313:45-53.	https://jamanetwork.com/journals/jama/fullarticle/2088851
DCCT Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *N Engl J Med.* 1993;329:977-986.	https://www.nejm.org/doi/10.1056/NEJM199309303291401
Duckworth W, et al. Glucose control and vascular complications in veterans with type 2 diabetes. *N Engl J Med.* 2009;360:129-139 (erratum:361:1024-1025).	https://www.nejm.org/doi/10.1056/NEJMoa0808431
Gerstein HC, et al. Effects of intensive glucose lowering in type 2 diabetes. *N Engl J Med.* 2008;358:2545-2559.	https://www.nejm.org/doi/10.1056/NEJMoa0802743
Holman RR, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. *N Engl J Med.* 2008;359:1577-1589.	https://www.nejm.org/doi/10.1056/NEJMoa0806470
Inzucchi SE. Update on diabetes drugs and CVD risk. American Diabetes Association (ADA). Presented at 64th Advanced Postgraduate Course, February 19, 2017.	https://professional.diabetes.org/sites/professional.diabetes.org/files/media/inzucchi_update_on_diabetes_drugs_and_cvd_risk_final.pdf

Inzucchi SE. Personalizing glucose-lowering therapy in patients with type 2 diabetes and cardiovascular disease. *Endocrinol Metab Clin North Am.* 2018;47:137-152.	https://www.sciencedirect.com/science/article/abs/pii/S0889852917301160
Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. *Lancet Diabetes Endocrinol*. 2019;7:776-785.	https://www.thelancet.com/journals/landia/article/PIIS2213-8587(19)30249-9/fulltext
McMurray JJV, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. *N Engl J Med.* 2019;381:1995-2008.	http://www.nejm.org/doi/full/10.1056/NEJMoa1911303
Nathan DM, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. *N Engl J Med.* 2005;353:2643-2653.	https://www.nejm.org/doi/full/10.1056/NEJMoa052187
Patel A, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. *N Engl J Med.* 2008;358:2560-2572.	https://www.nejm.org/doi/10.1056/NEJMoa0802987
UKPDS Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. *Lancet.* 1998;352:854-865.	https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(98)07037-8/fulltext
Wanner C, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. *N Engl J Med.* 2016;375:323-334.	https://www.nejm.org/doi/10.1056/NEJMoa1515920
Zelniker TA, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. *Lancet.* 2019;393:31-39.	https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)32590-X/fulltext
Zinman B, et al. Empagliflozin, cardiovascular outcomes, and mortality in	https://www.nejm.org/doi/10.1056/NEJMoa1504720

type 2 diabetes. *N Engl J Med.* 2015;373:2117-2128.	

Clinical Trials

Resource	Address
CANVAS NCT01032629	https://clinicaltrials.gov/ct2/show/NCT01032629
CARMELINA NCT01897532	https://clinicaltrials.gov/ct2/show/NCT01897532
CAROLINA NCT01243424	https://clinicaltrials.gov/ct2/show/NCT01243424
CREDENCE NCT02065791	https://clinicaltrials.gov/ct2/show/NCT02065791
DECLARE NCT01730534	https://clinicaltrials.gov/ct2/show/NCT01730534
ELIXA NCT01147250	https://clinicaltrials.gov/ct2/show/NCT01147250
EMPA-REG NCT01131676	https://clinicaltrials.gov/ct2/show/NCT01131676
EXAMINE NCT00968708	https://clinicaltrials.gov/ct2/show/NCT00968708
EXSCEL NCT01144338	https://clinicaltrials.gov/ct2/show/NCT01144338
HARMONY NCT02465515	https://clinicaltrials.gov/ct2/show/NCT02465515
LEADER NCT01179048	https://clinicaltrials.gov/ct2/show/NCT01179048
REWIND NCT01394952	https://clinicaltrials.gov/ct2/show/NCT01394952
SAVOR NCT01107886	https://clinicaltrials.gov/ct2/show/NCT01107886
SUSTAIN 6 NCT01720446	https://clinicaltrials.gov/ct2/show/NCT01720446

TECOS NCT00790205	https://clinicaltrials.gov/ct2/show/NCT00790205
VERTIS CV NCT01986881	https://clinicaltrials.gov/ct2/show/NCT01986881

Patient Resources

Resource	Address
American Diabetes Association (ADA). Resources.	https://www.diabetes.org/resources
American Diabetes Association (ADA). Resources.	https://www.heart.org/en/health-topics/diabetes/diabetes-tools--resources
American Heart Association (AHA). Prediabetes Tools and Resources.	https://www.heart.org/en/health-topics/diabetes/diabetes-tools--resources/prediabetes-tools-and-resources
Association of Diabetes Care & Education Specialists (ADCES). Resources for People Living with Diabetes.	https://www.diabeteseducator.org/living-with-diabetes
Centers for Disease Control and Prevention (CDC). National Diabetes Education Program.	https://www.cdc.gov/diabetes/ndep/index.html